Our unanticipated finding that ZBP1-mediated necroptosis in humans (but not mice) requires RIPK1 now positions existing RIPK1 kinase inhibitors as effective therapeutics for ZBP1-initiated pathologies, including but not limited to, viral diseases such as influenza-driven Acute Respiratory Distress Syndrome. This evidence concerns the gene RIPK1 and viral load.